CDK11 | Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

27 results for “CDK11”

Trials

Immunotherapy in Patients With Metastatic Cancers and CDK12 Mutations

56 participants · First posted Jun 27, 2018

Better Delineation of CDK13 Related Phenotype and Epigenetic Signature.

100 participants · First posted May 11, 2020

High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers

51 participants · First posted Aug 18, 2021

Drugs

View all 14 →

Anti-CDK11 antibody drug conjugates(Iksuda)

anti-CDK11 antibody drug conjugates PermaLink (Iksuda)

CDK12 Inhibitor

News

Acrivon Therapeutics Reports 44% Response Rate for CHK1/2 Inhibitor ACR-368 in Endometrial Cancer Phase II Trial

Acrivon Therapeutics Launches CLIA-Certified Laboratory to Advance Precision Medicine Development

Aumolertinib Plus Anlotinib Shows Promise for Untreated EGFR-Mutant NSCLC with CNS Metastases

Page 1 of 3